Clinical Trials
14 trialsNCT05201859 2026-05-07
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06475300 2026-05-06
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05213884 2026-04-24
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Phase 2 Completed
NCT04080804 2026-04-22
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06437522 2025-05-07
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03207867 2024-10-09
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Phase 2 Terminated
NCT04830267 2024-03-28
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT06170710 2023-12-14
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05097209 2023-03-23
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Unknown
NCT02605967 2022-02-10
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Novartis
Phase 2 Completed
NCT05092217 2021-10-25
Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2 Unknown
NCT03619824 2018-10-09
PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown